Goldman Sachs Maintains Sell Rating for Elanco Animal Health: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Goldman Sachs has reaffirmed its Sell rating on Elanco Animal Health (NYSE:ELAN) but increased its price target from $10.00 to $12.50. Despite the raised target, the new price still suggests a potential 16.75% downside from the current price of $15.02. Elanco operates globally, offering products for companion and food animals in over 90 countries.
January 17, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs maintains a Sell rating on Elanco Animal Health with a raised price target of $12.50, indicating a potential 16.75% decrease from the current price.
The reaffirmation of the Sell rating by a prominent investment bank like Goldman Sachs, despite a higher price target, is likely to influence investor sentiment negatively. The new target price is still below the current trading price, suggesting that Goldman Sachs analysts see overvaluation or potential headwinds for Elanco Animal Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100